Seattle Genetics Updates Data on Hodgkin treatment combo at ASH19

– Additional Analysis in Phase 2 Trial of ADCETRIS plus OPDIVO in Patients with Frontline Hodgkin Lymphoma Aged 60 Years and Older –

– Two-Year Follow-up Results from Phase 1/2 Trial in Relapsed Hodgkin Lymphoma –

https://www.marketscreener.com/SEATTLE-GENETICS-INC-10808/news/Seattle-Genetics-Announces-Updated-Data-of-ADCETRIS-Brentuximab-Vedotin-in-Combination-with-OPD-29697641/